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Results: Primary tumors were appendiceal for 60 patients (58.3%), mesothelioma for 14 (13.6%), colorectal for 9 (8.7%), ovarian for 8 (7.8%). R0/R1 resection was achieved in 46 (46.5%) patients. The time interval between the initial and the repeat CRS/HIPEC was <1 year for 21 (20.4%), 1-2 years for 40 (38.8%), and >2 years for 42 patients (40.8%). Overall median survival was 4.3 years and correlated with the time interval (1.3 years for <1 years, 3.7 years for 1-2 years, and 7 years for >2 years; P < 0.001). In multivariate analysis, the R status (P = 0.005) and a time interval of more than 2 years (P = 0.0002) were strongly associated with survival with each additional month between the surgeries conferring a 2.6% reduction in the risk of death.
Conclusions:
The current series validates time interval between cytoreductions as a major surrogate of tumor biology in selection of patients with recurrent peritoneal surface malignancies for repeat CRS/HIPEC. Complete repeat cytoreduction more than 2 years from the initial surgery is associated with a favorable outcome.
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| INTRODUCTION
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can result in prolonged survival for carefully selected patients with peritoneal surface malignancies. [1] [2] [3] [4] The type of the primary tumor, the volume and distribution of peritoneal disease, and the performance status of the patient are paramount in patient selection, whereas the accumulated institutional experience over time establishes more complete cytoreductions with fewer complications.
1 recurrence confined to the peritoneal cavity is high. 3 The majority of these patients will eventually succumb to their disease from intestinal obstruction and malnutrition. 5 The question of repeat cytoreduction therefore arises with the caveat that its benefit has to be weighed against the surgical risk of repeat surgical debulking as well as the aggressiveness of the primary tumor. 6 In our prior study, we reported our experience with 62 patients who underwent repeat CRC/HIPEC and we found postoperative morbidity and mortality comparable with the initial CRS/HIPEC. 7 The ability to achieve a complete macroscopic cytoreduction and the time interval between the initial and repeat cytoreductions were strongly associated with survival. Smaller studies on repeat CRS/HIPEC similarly reported potential for prolonged survival while patient selection criteria are still evolving. 8, 9 Since our prior report, we nearly doubled our experience with repeat CRS/HIPEC procedures. The aim of the current study was to identify a time interval between the initial and repeat CRS/HIPEC which as a surrogate of tumor biology is associated with meaningful survival outcomes. We have previously reported in detail the evaluation of patients, the selection criteria for CRS/HIPEC, and the details of cytoreduction and intraperitoneal hyperthermic chemotherapy at our institution. Survival estimates were calculated using the Kaplan-Meier method and the log-rank test was used to assess differences in survival between groups. Multivariate survival analysis was performed utilizing
| MATERIALS AND METHODS
Cox proportional hazards regression. Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC). A P value of ≤0.05 was considered to be statistically significant.
3 | RESULTS
| Surgical outcomes
We reviewed 1314 CRS/HIPEC procedures performed between The origin of the primary tumors was most often appendiceal (58.3%), mesothelioma (13.6%), colorectal (8.7%), and ovarian (7.8%) cancer. A complete macroscopic cytoreduction (R0/R1 margin) was achieved for 51.5% of patients after the first CRS/HIPEC and 46.5% after the second. Overall, the postoperative morbidity and mortality were 39.8% and 0% after the initial cytoreduction and 38% and 1%
after the repeat one. Seven patients (6.8%) underwent a third CRS/ HIPEC.
| Survival outcomes
The median overall survival for the entire cohort was 4.3 years from the time of the repeat operation (Fig. 1) . According to tumor type, the median overall survival was 5.6 years for appendiceal cancer (range:
0.01-9.7 years) (7 years for low grade and 2.3 years for high grade), 2. On multivariate analysis, the presence of R0 resection (P = 0.005) and the time interval between the initial and repeat cytoreduction (P = 0.0002) were associated with survival. Each additional month between the two surgeries conferred a 2.6% decrease in the risk of death.
| DISCUSSION
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with prolonged survival in selected patients with peritoneal surface malignancies. However, even with optimal cytoreduction, the risk of peritoneal recurrence is substantial. 3 In our prior experience with repeat CRS/HIPEC procedures, 7 we reported morbidity and mortality similar to the initial CRS/HIPEC and the opportunity for prolonged survival in carefully selected patients who have achieved a complete repeat CRS. In the current study, we revisited repeat CRS/HIPEC outcomes as a function of the interval between the two CRS procedures to describe how tumor biology influences survival. Others: gallbladder (n = 1), gastric (n = 2), gastrointestinal stromal tumor (GIST) (n = 1), sarcoma (n = 2), small bowel (n = 2), urachal (n = 1), peritoneal serous carcinoma (n = 1). These results might not be easily extrapolated to other institutions even though the data are prospectively collected. In addition, the presented outcomes do not reflect the number of patients who were initially considered candidates for repeat CRS/HIPEC but their operative findings did not allow for complete cytoreduction. Despite the above limitations, this study provides with not statistical projections, but actual long-term outcomes.
| CONCLUSIONS
Repeat CRS/HIPEC is a good treatment option for peritoneal surface disease with primary sites that have limited ability for recurrence LGA, low-grade appendiceal cancer; HGA, high-grade appendiceal cancer; "+" indicates that patient was alive at last contact date, survival measured from second CRS/HIPEC; Other, gallbladder (n = 1), gastric (n = 2), gastrointestinal stromal tumor (GIST) (n = 1), sarcoma (n = 2), small bowel (n = 2), urachal (n = 1), peritoneal serous carcinoma (n = 1).
FIGURE 2
The median overall survival for 103 patients after repeat cytoreduction with hyperthermic intraperitoneal chemotherapy correlated to the time interval between the initial and the repeat CRS/HIPEC procedures (median overall survival 1.3 years for time interval <1 year vs. 3.7 years for 1-2 years and 7 years for more than 2 years; P < 0.001) outside the peritoneal cavity, as well as for highly selected recurrent carcinomatosis patients who maintain a good functional status particularly when the peritoneal recurrence occurs at least 1 year and ideally 2 years from the initial cytoreduction. Patients with peritoneal carcinomatosis with early, less than a year recurrence and prior incomplete CRS should in general not be offered repeat cytoreduction.
